(RTTNews) - Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in ...
Omvoh is now approved in the U.S. for two types of inflammatory bowel disease (IBD), following its October 2023 approval as a first-in-class treatment for moderately to severely active ulcerative ...
THURSDAY, Jan. 16, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...
The drug, branded as Omvoh, is already approved in the U.S. to treat moderate-to-severe active ulcerative colitis, another type of IBD. The U.S. drugmaker struck a $3.2 billion deal last year to ...
(RTTNews) - Eli Lilly and Co. (LLY), on Friday, announced that most patients with moderately to severely active Crohn's disease treated with Omvoh for two years, experienced sustained clinical ...